疏肝解郁胶囊治疗脑卒中后抑郁患者疗效及日常生活活动能力研究

摘要

目的 探讨疏肝解郁胶囊治疗脑卒中后抑郁的疗效、日常生活能力、安全性的研究.方法 未服用过抗抑郁药物的脑卒中后抑郁患者40例做为对照组,实验组为40例服用疏肝解郁胶囊治疗前、治疗6 w末及12 w末脑卒中后抑郁的患者,采用汉密尔顿抑郁量表(HAMD)评分,日常生活活动能力量表(Barthel 指数)评分.结果 实验组未治疗前与对照组HAMD评分及Barthel 指数评分比较无明显统计学差异(P>0.05),服用疏肝解郁胶囊治疗6 w末与对照组HAMD评分及Barthel 指数评分有统计学差异(P<0.05),并且治疗12 w末与对照组HAMD评分及Barthel 指数评分有明显的统计学差异(P<0.01).同时HAMD评分有效率结果表明,对照组未服用疏肝解郁胶囊6 w及12 w末有效率为0%,治疗组服用疏肝解郁胶囊6 w及12 w末有效率分别为75%及85%.结论 疏肝解郁胶囊能有效治疗脑卒后抑郁,并且能改善脑卒中后抑郁患者日常生活活动能力,不良反应较少,安全性高.%Objective To explore clinical efficacy,the ability of daily life and safety of Shuganjieyu capsule in the treatment of post-stroke depression.Methods The total of 40 patients with post-stroke depression who had never taken antidepressants as control group.The total of 40 patients with post-stroke depression take the Shuganjieyu capsule after 6 weeks and 12 weeks as study group.All patients were assessed with Hamilton Depression Scale(HAMD)and Barthel.Results The control group of Scale(HAMD)and Barthel were no statistical difference compared to study group had never taken antidepressants(P>0.05).The study group of Scale(HAMD)and Barthel taken antidepressants after 6 weeks were statistical difference compared to control group(P<0.05).And the study group of Scale(HAMD)and Barthel taken antidepressants after 12 weeks were significant statisticaly different compared to control group(P<0.01).The control group of Scale(HAMD)results show that effective were 0% after 6 weeks and 12 weeks have never taken Shuganjieyu capsule.The study group of Scale(HAMD)results show that effective were 75% after 6 weeks and 85% after 12 weeks had taken Shuganjieyu capsule.Conclusion Shuganjieyu Capsule therapy for post-stroke depression is effective and safe treatment,and also improve the ability of daily life.